Hormone receptor (HR)-positive, HER2-positive breast cancer

Hormone receptor (HR)-positive, HER2-positive breast cancer is a distinct biological subtype of mammary carcinoma affecting the breast tissue, predominantly diagnosed in adult women but also occurring in men Clinically, these dual-driven molecular characteristics distinguish the condition from other breast cancer subtypes and make it uniquely amenable to combination strategies pairing endocrine therapy with HER2-targeted agents

Hormone receptor (HR)-positive, HER2-positive breast cancer is a distinct biological subtype of mammary carcinoma affecting the breast tissue, predominantly diagnosed in adult women but also occurring in men Pathophysiologically, this malignancy is defined by tumor cells that express nuclear estrogen receptors, progesterone receptors, or both, alongside simultaneous overexpression of human epidermal growth factor receptor 2 protein or amplification of the *ERBB2* gene

Pathophysiologically, this malignancy is defined by tumor cells that express nuclear estrogen receptors, progesterone receptors, or both, alongside simultaneous overexpression of human epidermal growth factor receptor 2 protein or amplification of the *ERBB2* gene

Pathophysiologically, this malignancy is defined by tumor cells that express nuclear estrogen receptors, progesterone receptors, or both, alongside simultaneous overexpression of human epidermal growth factor receptor 2 protein or amplification of the *ERBB2* gene

Pathophysiologically, this malignancy is defined by tumor cells that express nuclear estrogen receptors, progesterone receptors, or both, alongside simultaneous overexpression of human epidermal growth factor receptor 2 protein or amplification of the *ERBB2* gene

This concurrent activation establishes complex bidirectional signaling crosstalk between steroid hormone and growth factor tyrosine kinase pathways, driving aggressive cellular proliferation, survival, and potential bidirectional treatment resistance

This concurrent activation establishes complex bidirectional signaling crosstalk between steroid hormone and growth factor tyrosine kinase pathways, driving aggressive cellular proliferation, survival, and potential bidirectional treatment resistance

This concurrent activation establishes complex bidirectional signaling crosstalk between steroid hormone and growth factor tyrosine kinase pathways, driving aggressive cellular proliferation, survival, and potential bidirectional treatment resistance Clinically, these dual-driven molecular characteristics distinguish the condition from other breast cancer subtypes and make it uniquely amenable to combination strategies pairing endocrine therapy with HER2-targeted agents